Malignant glaucoma treated by low-dose laser cycloplasty: a 1-year multicenter prospective noncomparative study

AIM:To report a one-year clinical outcomes of low-dose laser cycloplasty(LCP)among malignant glaucoma patients.METHODS:In this prospective,multicenter,noncomparative clinical study,participants with malignant glaucoma were recruited and underwent LCP at eight ophthalmic centers in China.Patients were followed up at 1wk,1,3,6,and 12mo.Intraocular pressure(IOP),number of glaucoma medications,anterior chamber depth(ACD),and complications were recorded.Anatomical success was defined as the reformation of the anterior chamber based on slit-lamp biomicroscopy.Recurrence was defined by the presence of a shallow orflat anterior chamber after initial recovery from treatment.RESULTS:A total of 34 eyes received LCP.Mean IOP and medications decreased from 36.1±11.5 mm Hg with 3.3±1.5 glaucoma medications pre-treatment to 20.9±9.8 mm Hg(P<0.001)with 2.9±1.6 medications(P=0.046)at 1d,and 17.4±6.7 mm Hg(P<0.001)with 1.3±1.7 medications(P<0.001)at 12mo.The ACD increased from 1.1±0.8 mm at baseline to 1.7±1.0 mm and to 2.0±0.5 mm at 1d and 12mo,respectively.A total of 32(94.1%)eyes achieved initial anatomical success.During follow-up,2(5.9%)eyes failed and 8(23.5%)eyes relapsed,yielding a 12-month anatomical success rate of 64.3%.Complications including anterior synechia(8.82%),choroidal/ciliary detachment(5.88%)and hypopyon(2.94%)were observed within 1wk.CONCLUSION:LCP is simple,safe,and effective in reforming the anterior chamber in malignant glaucoma.

ZJC 480 Series Helium-Neon Laser Blood Vessel Internal Exposure Apparatus

The ZJC 480 series helium-neon laser blood vessel internal exposure apparatus was developed by the Changchun Zhongji Photoelectric Co, Ltd. It is used in the treatment of ischemic anoxic cardiovascular and cerebrovascular diseases, nervous system disorders, and respiratory and urinary system disorders. In 1995, the ZJC series was appraised as the "95 State-Grade Key New Product" by the State Science and Tech-

低剂量氦氖激光对口腔癌患者放射性口腔黏膜炎疗效及安全性分析

目的探析口腔癌患者放射性口腔黏膜炎采取低剂量氦氖激光诊疗的临床效果及运用安全性。方法选取时间段2019年9月至2021年9月于本院就诊的口腔癌放射性口腔黏膜炎患者研究,统计128例,以奇偶法原则分组,分为2组,一组对照组(n=64),一组研究组(n=64),对照组采取假治疗,研究组采取低剂量氦氖激光疗法,比较两组疗效。结果(1)有效率:研究组有效率高于对照组P<0.05;(2)疼痛评分:研究组诊疗后7d、14d、21dVAS评分较对照组低P<0.05;(3)不良反应:研究组不良反应率与对照组比无较大差异P>0.05;(4)预后水平:相较于对照组,研究组口腔黏膜炎愈合速率明显较高P<0.05;(5)睡眠质量:研究组睡眠质量因子评分均低于对照组P<0.05。结论口腔癌患者放射性口腔黏膜炎采取低剂量氦氖激光诊疗效果可观,有益于减轻黏膜炎严重程度,促进炎症愈合,且降低疼痛感,不良反应少,具较高的运用安全性。